Synthetic biology-based ADCC technology
US11667693B2 · kind B2 · utility
0Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 27, 2019 |
| Grant date | Jun 6, 2023 |
| Priority date | — |
| Expiry date | Mar 9, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/70
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel synthetic biology-based ADCC technology is provided that enhances or enables ADCC response. The novel ADCC technology can be used to prevent or treat cancers, infectious, inflammatory or autoimmune diseases, and other diseases where elimination of diseased cells is desirable.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.